F10 and interstitial lung disease: Specifically, we investigated whether factor Xa (FXa) inhibitor (apixaban, edoxaban, and rivaroxaban) or direct thrombin inhibitor (dabigatran) was associated with a risk of ILD compared with warfarin among patients treated with OACs who were enrolled in a large population-based nationwide cohort study in Taiwan.